Stryker plunges 12% Q3 results, guidance disappoint

Stryker’s Q3 adjusted EPS of $3.52 missed the $3.55 consensus, while revenue of $6.5 billion fell short of the $6.62 billion estimate despite 7.7% year-over-year growth; shares declined 12% after the announcement. The company set 2026 adjusted EPS guidance at $14.80–$14.90, below the $14.95 consensus, while forecasting 6.5%–7.0% organic sales growth. It repurchased $1.0 billion of stock in the quarter and received approval for an additional $3.0 billion buyback authorization.

Analysis

The key signal is not the small reported shortfall by itself; it is management’s lower-than-consensus full-year EPS outlook after a quarter of solid organic growth and margin expansion. That combination raises the risk that investors were underwriting a more reliable earnings trajectory than execution currently supports. The 12% decline may therefore reflect multiple compression and estimate-reset risk, not just a one-quarter revenue miss.

There is a credible contrarian case: 7.7% organic growth and 60 bp of adjusted margin expansion argue against an immediate deterioration in demand or operating leverage. Stronger MedSurg and Neurotechnology growth than Orthopaedics also makes the consolidated result less indicative of weakness across every product area. But segment growth alone does not establish whether the gap was timing, procedure volume, mix, or execution; verify management’s Q&A and subsequent estimate revisions before treating the selloff as overdone.

Over the next 1–3 months, the decisive catalyst is whether Q4 delivery and 2027 commentary stabilize expectations. A further guidance cut or weaker organic growth would make the reset more structural; sustained growth and margins near current levels would support a rebound. Over 6–18 months, persistent relative weakness in Orthopaedics could matter more than the headline growth rate. Buybacks may support demand for shares, but the authorization is not a floor and cannot offset recurring estimate reductions.

Key Decisions for Investors

• Avoid chasing the initial post-results decline. Put SYK on a staged-entry watchlist and wait for analyst estimate revisions and management commentary to show whether the guide gap is timing-related or a lower earnings run rate.
• If estimates stabilize and Q4 execution confirms the outlook, consider a measured long SYK position against a short broad medtech basket to isolate company-specific recovery from sector moves. Keep sizing modest until the source of the shortfall is clear.
• Do not treat the additional repurchase authorization as a standalone bullish catalyst. Track actual repurchases alongside diluted share count and earnings revisions; buybacks are less supportive if operating expectations keep falling.
• Falsify the recovery thesis if SYK cuts its 2026 outlook again, organic growth decelerates materially, or adjusted operating margin reverses its recent expansion. Conversely, stable guidance with continued growth and margin delivery would strengthen the case that the selloff overshot.